Change in body weight and body mass index in psoriasis patients receiving biologics: A systematic review and network meta-analysis - 11/12/19
Abstract |
Background |
Previous studies have suggested that biologic therapy for psoriasis might relate to body weight gain.
Objective |
To assess the changes in body weight and body mass index (BMI) in psoriasis patients after receiving various biologics.
Methods |
We conducted a systematic review and network meta-analysis to evaluate the changes in body weight and BMI in psoriasis patients receiving biologics. On March 1, 2019, we searched Medline, Embase, and Cochrane Central Register of Controlled Trials for relevant studies. The Newcastle-Ottawa scale was used to assess the risk of bias.
Results |
We included 6 studies with 862 psoriasis patients. Compared with conventional systemic treatments, treatment with tumor necrosis factor α inhibitors was associated with a significant increase in body weight (mean difference 1.40 kg, 95% confidence interval 0.88-1.93 kg) and BMI (0.39 kg/m2, 95% confidence interval 0.24-0.54 kg/m2). In contrast, no significant increase in body weight or BMI was found among patients receiving anti-interleukin (IL)-12/23 or anti-IL-17 biologics.
Limitations |
Only 1 study reported body weight and BMI for patients receiving the anti-IL-17 biologic.
Conclusion |
Tumor necrosis factor α inhibitor treatment appears to be associated with an increase in body weight and BMI, and treatment with anti-IL-12/23 and anti-IL-17 biologics do not. This association should be considered before initiating biologics for overweight and obese patients.
Le texte complet de cet article est disponible en PDF.Key words : anti-interleukin-12/23 biologic, anti-interleukin-17 biologic, biologic therapy, body mass index, body weight, network meta-analysis, psoriasis, tumor necrosis factor inhibitor
Abbreviations used : BMI, CI, IL, MD, SD, SUCRA, TNF-α, TNFi
Plan
| Funding sources: None. |
|
| Conflicts of interest: Prof Chi received speaking fees from AbbVie Taiwan, Janssen Taiwan, Novartis Taiwan, and Pfizer Taiwan. Dr Wu, Ms Yu, and Dr Yang have no conflicts of interest to disclose. |
Vol 82 - N° 1
P. 101-109 - janvier 2020 Retour au numéro
Article précédent
- Intralesional versus intramuscular bivalent human papillomavirus vaccine in the treatment of recalcitrant common warts
- Ahmad Nofal, Ayman Marei, Al-shimaa M. Ibrahim, Eman Nofal, Manal Nabil
- Number of skin biopsies needed per malignancy: Comparing the use of skin biopsies among dermatologists and nondermatologist clinicians
- Ashley Privalle, Thomas Havighurst, KyungMann Kim, Daniel D. Bennett, Yaohui G. Xu
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?